Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
IBRX
SELLImmunityBio, Inc. · Healthcare · United States · $7.4B · Avg Vol: $82M/d
COMPANY DESCRIPTION
ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing a broad pipeline of off-the-shelf natural killer (NK) cell therapies and other immunotherapies for cancer and infectious diseases. The company's proprietary NantCancerVax platform aims to activate multiple arms of the immune system to achieve durable responses. Its innovative approach and diverse development programs position it as a potential disruptor in oncology and immunology.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.2M | 0.6M | 14.7M | 113.3M | 678.6% | 141.0M | 222.4M | — | 96.3% |
| EPS | -0.42 | -1.15 | -0.59 | -0.38 | — | -0.83 | -0.85 | 0.06 | — |
| Shares | 1.0B | 670.9M | 852.9M | 1.0B | -3.4% | 1.0B | — | — | — |
| Debt | 723.8M | 726.7M | 504.2M | 518.1M | -10.5% | 1.1B | — | — | — |
| Equity | -447.3M | -587.0M | -489.1M | -500.5M | — | — | — | — | — |
| Op CF | -337.5M | -366.8M | -391.2M | -304.9M | — | -294.4M | — | — | — |
| Inv CF | 27.3M | -30.5M | -12.2M | -149.8M | — | — | — | — | — |
| Fin CF | 233.6M | 558.3M | 281.6M | 400.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of IBRX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| IBRX | ImmunityBio, Inc.(you) | $7.4B | 28 | SELL |
| PCVX | Vaxcyte, Inc. | $7.9B | 28 | SELL |
| COGT | Cogent Biosciences, Inc. | $6.8B | 26 | SELL |
| PRAX | Praxis Precision Medicines, Inc. | $9.1B | 28 | SELL |
| ERAS | Erasca, Inc. | $6.6B | 31 | SELL |
| CGON | CG Oncology, Inc. | $6.1B | 26 | SELL |
| CRNX | Crinetics Pharmaceuticals, Inc. | $8.9B | 30 | SELL |
| RYTM | Rhythm Pharmaceuticals, Inc. | $7.0B | 33 | SELL |
| KYMR | Kymera Therapeutics, Inc. | $9.1B | 25 | SELL |
| SYRE | Spyre Therapeutics, Inc. | $8.9B | 32 | SELL |
Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.5%